Comparison of Stage IV Colonic Carcinoma in Right Side to Left Side by Prognostic Markers like her-2-neu, p 53 and KRAS Mutation
Journal Title: Journal of Medical Science And clinical Research - Year 2018, Vol 6, Issue 1
Abstract
Backgrounds: Colorectal carcinomas vary considerably throughout the world, being one of the leading cancer sites in the developed countries. Colorectal cancer (CRC) is the third most commonly diagnosed cancer globally, accounting for 10.0% of all new cancer cases. Here, difference in expression of p53, Her-2-neu, K-RAS and prognosis along with survival of stage IV both right and left sided colon cancers were evaluated. Methods and Materials: One year retrospective study of stage IV carcinoma colon cases was studied in our institute; separated as right and left side colonic carcinoma. Immunohistochemistry of p53, Her-2-neu and KRAS mutation study by RT-PCR was done on their respective blocks and the results were compared; prognosis studied by follow up of the patients for 1 year. Results: A total of 512 histopathologically confirmed cases of colon carcinoma were screened and paraffin block of 15 cases of stage IV colon carcinoma elaborately studied by routine Haematoxylin & Eosin stain. Followed by IHC (P53 and Her 2/Neu), RT PCR study (K ras mutation) were carried out. Among them 6 were right and rest 9 were left side colon carcinoma. Right sided cases constituted 3 adenocarcinoma NOS (p53, Her 2 neu positive) 2 mucin secreting adenocarcinoma (p53 positive her 2 neu negative) and 1 signet ring cell adenocarcinoma (p53 positive Her 2 neu negative). Left sided cases constituted 5 adenocarcinoma NOS( p53 positive Her 2 neu negative), 2 mucin secreting( p53 positive Her 2 neu negative) and 2 signet ring cell ( p53 , Her 2 /neu negative). K ras mutation was positive in 67% right sided and 40%left sided colonic cancers. Following up, 83% of right sided cancer patients were dead and 17% living whereas in left sided cancers, 67% were living responding well to chemotherapy. Conclusion: Anti-epidermal growth factor receptor monoclonal antibody treatment (targeted therapy), with cetuximab and panituzumab is more effective in left side colonic carcinoma than right side
Authors and Affiliations
Dr Pranita Mohanty
Keywords
Related Articles
- EP ID EP502431
- DOI -
- Views 57
- Downloads 0
Expression of Stathmin and CD10 in Invasive Mammary Carcinoma with Relation to Triple Markers
Background: Stathmin is a highly conserved cytosolic phosphoprotein that destabilizes microtubules. Stathmin acts in vitro as a tubulin-sequestering protein, and its activity is dramatically reduced by phosphorylation. I...
Burden of Group A Streptococci among Children Aged 5-15 years with Symptoms of Pharyngotonsillitis: A Study in a Tertiary Care Hospital, Bangalore
Background: Rheumatic fever and Rheumatic heart disease continue to be major problems in most developing countries including India where prevalence rate is 4-6/1000 children per year. Clinical presentations of streptococ...
Occupational Therapists Perspective in Wound Care Management
Occupational Therapists play a major role in prevention and management in skin and wound care. Wounds and injuries can restrict persons participation in day to day activities e.g. Self care. Wounds can be of physical Inj...
Schizencephaly: An Incredibly A Rare Disease (Case Report and Review of Literature)
Schizencephaly is an extremely rare cortical malformation that manifest as a grey matter lined cleft extending from ependymal to the piamater .It is also known as split brain disease. It usually presents itself in childh...
An Overview of Recurrent Renal Calculi and Its Management
Introduction: Renal calculi are one of the most painful, commonest urological diseases. Life-time risk due to renal calculi is approximately 12% in men and 6% in women. Recurrence rate is reported as 50 % at 5 years, 80-...